Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Portfolio Pulse from
Sutro Biopharma presented data from its REFRαME-O1 trial at SGO 2025, showing consistent response rates in patients with platinum-resistant ovarian cancer across all levels of FRα expression of 25% or greater.
March 15, 2025 | 11:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sutro Biopharma's presentation at SGO 2025 revealed promising data from the REFRαME-O1 trial, indicating consistent response rates in ovarian cancer patients. This could positively impact investor sentiment and the stock price.
The presentation of positive trial data at a major conference like SGO 2025 is likely to enhance investor confidence in Sutro Biopharma's pipeline, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100